all report title image
  • Published On : Sep 2022
  • Code : CMI2610
  • Industry : Medical Devices
  • Pages : 117
  • Formats :

Central venous catheters play a major role in modern healthcare. These catheters allow easy administration of intravenous fluids, blood products, medications, and parenteral nutrition, as well as offer hemodialysis access and hemodynamic monitoring. They are used in various diseases for longer duration therapies such as cancer (chemotherapy) and end stage renal disease (dialysis).

U.S. Central Venous Catheter Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. COVID-19 has also affected the economies in three main ways- by directly affecting the production and demand, by creating disruptions in distribution channels, and through its financial impact on companies and financial markets. The increase in central-line–associated bloodstream infections and blood culture contamination rates increase the market growth. For instance, in November 2020, National Center for Biotechnology Information published a report which reported that a there was a significant increase in central-line–associated bloodstream infections and blood culture contamination rates during the pandemic. Blood culture contamination rates were 19% higher during the COVID-19 period, whereas the CLABSI (central-line–associated bloodstream infections) rate during the pandemic increased by 25% in US.

Thus, impact of the Coronavirus (COVID-19) pandemic had driven the growth of the U.S. central venous catheter market during the pandemic.

U.S. central venous catheter market is estimated to be valued at US$ 1,023.41 million in 2022 and is expected to exhibit a CAGR of 6.2% during the forecast period (2022-2030).

Figure 1: U.S. Central Venous Catheter Market Share, (%), Analysis, By Design, 2022

U.S. Central Venous Catheter  | Coherent Market Insights

Increasing number of advantages associated with single lumen is expected to drive the growth of U.S. central venous catheter market

Increasing advantages associated with single lumen drives the growth of U.S. central venous catheter market over the forecast period. For example:

  • Single lumen are simplest means of lung isolation
  • Does not require any special equipment
  • Preferred for emergencies such as contralateral tension pneumothorax
  • Lower rate of infection associated with single lumen as compared to double and multiple lumen.
CMI table icon

U.S. Central Venous Catheter Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,023.41 Mn
Historical Data for: 2018 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.2% 2030 Value Projection: US$ 1,657.13 Mn
Geographies covered:
  • U.S.
Segments covered:
  • By Product Type: Peripherally Inserted Central Catheters (PICC), Implantable Ports, Tunneled Central Venous Catheter, Non-tunneled Central Venous Catheter
  • By Design: Single Lumen, Double Lumen, Multi Lumen
  • By Composition: Polyurethane, Polyethylene, Silicon
  • By Procedure: Cardiovascular Procedure, Chemotherapy Procedure, Dialysis Procedure
  • By End User: Hospital, Ambulatory Surgical Centers, Specialty Clinics
Companies covered:

AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL,  Gilead Sciences, Inc and ZOLL Medical Corporation

Growth Drivers:
  • Increasing number of advantages associated with single lumen
  • Increasing use of peripherally inserted central catheters
Restraints & Challenges:
  • Peripherally inserted central catheters requires experienced specialist, need radiological confirmation, requires training of patients for suitable device care

U.S. Central Venous Catheter Market – Restraints

There are various restrains associated with central venous catheter market such as:

  • Peripherally inserted central catheters requires experienced specialist, need radiological confirmation, requires training of patients for suitable device care.
  • Non-tunneled central line have higher risk of being affected by infection, their usage duration is limited and patients cannot be sent home
  • Central line midline catheters cannot be used to draw blood; only solutions which are peripherally compatible cannot be applied.

Figure 2: U.S. Central Venous Catheter Market Value (US$ Mn), By Product Type, 2022

U.S. Central Venous Catheter  | Coherent Market Insights

Increasing use of peripherally inserted central catheters is expected to bolster the U.S. central venous catheter market growth over the forecast period.

Increasing use of peripherally inserted central catheters associated with low complications is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2021, Journal of Medicine and Life, a peer-reviewed open access journal, published a report which stated that PICCs (peripherally inserted central catheters) may be used as a safe option for central venous access in children either in the intermediate- or long-term. New types of PICC may facilitate broader indications and provide longer dwell times. PICC placement can be learned easily, usually requires light sedation and/or local anesthesia, and seldom causes serious perioperative risks. Application of assisted visualization and having well-educated staff could improve the insertion success rate and reduce the complications of PICCs.

U.S. Central Venous Catheter Market - Competitive Landscape

Key players operating in the global osteoporosis drugs market include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL,  Gilead Sciences, Inc and ZOLL Medical Corporation

A central venous catheter (KATHeter), also known as a central line or CVC, is a long, soft, thin, hollow tube that is placed into a large vein (blood vessel). A central venous catheter differs from an intravenous (IV) catheter placed in the hand or arm (also called a “peripheral IV”). A central line is longer, with a larger tube, and is placed in a large (central) vein in the neck, upper chest or groin. This type of catheter has special benefits in that it can deliver fluids into a larger vein, and that it can stay in the body for a longer period of time than a usual, shorter IV.

Common reasons for having a central line include:

  • To give IV medications over a long period of time because a large vein can tolerate an IV catheter for a longer time than a small vein. Examples of such medications are antibiotics and chemotherapy.
  • To deliver IV medications as an outpatient. Compared with a shorter IV, a central venous catheter is less likely to come out of the vein and this allows patients to be more active and receive IV medications at home.
  • To rapidly deliver large amounts of fluid or blood, for example when a person is in shock
  • To directly measure blood pressure in a large or central vein. This can help determine how much fluid a person needs.
  • To take frequent blood samples (more than once each day) without being stuck with needles many times
  • To deliver nutrition directly into the blood when food or liquids cannot be given through the mouth, stomach, or intestine
  • To connect a person with kidney failure to a hemodialysis machine that clears the body of wastes and extra fluid

Market Dynamics

The research and development of device like central venous catheter by the market player is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in May 2018, Pursuit Vascular Inc., a medical device company, announced that the US Food and Drug Administration (FDA) had granted clearance for a broader indication for ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infections (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Moreover, increasing prevalence of cardiovascular disease in the U.S. is expected to drive the growth of U.S. central venous catheter market over the forecast period. For instance, in January 2021, Heart Disease and Strokes Statistics, the U.S. age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2018 data, on average, someone dies of CVD every 36 seconds. There are 2,380 deaths from CVD each day, based on 2018 data, whereas someone dies of a stroke every 3 minutes and 33 seconds in the U.S. There are about 405 deaths from stroke each day, based on 2018 data.

Key features of the study:

  • This report provides an in-depth analysis of the U.S. central venous catheter market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the U.S. central venous catheter market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL, Gilead Sciences, Inc and ZOLL Medical Corporation
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The U.S. central venous catheter market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. central venous catheter market

Detailed Segmentation:

  • U.S. Central Venous Catheter Market, By Product Type:
    • Peripherally Inserted Central Catheters (PICC)
    • Implantable Ports
    • Tunneled Central Venous Catheter
    • Non-tunneled Central Venous Catheter
  • U.S. Central Venous Catheter Market, By Design:
    • Single Lumen
    • Double Lumen
    • Multi Lumen
  • U.S. Central Venous Catheter Market, By Composition:
    • Polyurethane
    • Polyethylene
    • Silicon
  • U.S. Central Venous Catheter Market, By Procedure:
    • Cardiovascular Procedure
    • Chemotherapy Procedure
    • Dialysis Procedure
  • U.S. Central Venous Catheter Market, By End User:
    • Hospital
    • Ambulatory Surgical Centers
    • Specialty Clinics
  • Company Profiles
    • AngioDynamics, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • R. Bard, Inc.
    • Teleflex Incorporated
    • Braun Melsungen AG
    • Medtronic Plc
    • Vygon Ltd.
    • Cook Medical, Inc.
    • Argon Medical Devices, Inc.
    • ICU Medical, Inc.
    • Theragenics Corporation
    • Becton, Dickinson and Company
    • icumedical
    • Polymedicure
    • Lepu Medical Technology (Beijing) Co.,Ltd.
    • VOGT MEDICAL
    • Gilead Sciences, Inc
    • ZOLL Medical Corporation

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The U.S. central venous catheter market is expected to register a CAGR of 6.2% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 1,023.41 million in 2022.
The prominent players in the market include AngioDynamics, Inc, C.R. Bard, Inc, Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc, Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc.,ICU Medical, Inc.,Theragenics Corporation, Becton, Dickinson and Company,icumedical, Polymedicure, Lepu Medical Technology (Beijing) Co.,Ltd., VOGT MEDICAL,  Gilead Sciences, Inc and ZOLL Medical Corporation
The market is expected to be valued at US$ 1,657.13 million in 2030.
Increasing product approval by the U.S. FDA (Food and Drug Administration) by the market player is expected to drive growth of the market during the forecast period.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo